Investment Rating - The report assigns a "Buy" rating to the company, Rongchang Biopharmaceutical (9995 HK) [4][12]. Core Insights - The target price for the company has been raised to HKD 66.00, indicating a potential upside of 40.7% from the current price of HKD 46.90 [1][12]. - The company has initiated an H-share placement to raise approximately HKD 796 million to support pipeline expansion and operations, which is expected to alleviate cash burn pressure significantly [7]. - The revenue for Q1 2025 showed a strong growth of 59.2% year-on-year, driven by increased sales of Taitasip and Vidisizumab [7]. - The report maintains expectations for continued loss reduction in 2025-2026, with a forecasted break-even point in 2027 [7]. Financial Summary - Revenue projections (in million RMB) are as follows: - 2023: 1,076 - 2024: 1,710 - 2025E: 2,365 - 2026E: 3,331 - 2027E: 5,459 - Year-on-year growth rates for revenue are projected at 40.2% for 2023, 58.9% for 2024, 38.3% for 2025, 40.9% for 2026, and 63.9% for 2027 [3][13]. - The net profit (loss) is expected to improve from a loss of RMB 1,511 million in 2023 to a profit of RMB 398 million by 2027 [3][13]. - The report indicates a significant adjustment in the net profit forecast for 2027, increasing by over 60% due to optimistic projections for Taitasip's market performance [7]. Valuation Model - The DCF valuation model estimates the equity value of the company at approximately RMB 33,799 million, translating to a per-share value of HKD 66.00 [9]. - The projected free cash flow is expected to turn positive by 2026, with a forecast of RMB 865 million [9]. Stock Performance - The stock has shown a year-to-date increase of 225.69% [6]. - The 52-week high and low for the stock are HKD 47.00 and HKD 10.62, respectively [6]. Analyst Coverage - The report is authored by analysts from BOCOM International, with contact details provided for further inquiries [7].
荣昌生物（09995）：H股配售充实现金储备，基于泰它西普更乐观的海外预期；上调目标价